The evolution of treatment for advanced cervical cancer: from cisplatin monotherapy to immuno-oncology combinations

Author:

Rumyantsev A. A.1ORCID,Letuchikh A. N.1ORCID

Affiliation:

1. Blokhin National Medical Research Center of Oncology

Abstract

Cervical cancer is one of the most common malignant tumors in Russia. Despite the high cure rates with local treatment approaches (eg, surgery or radiothearapy) at early stages of the disease, metastatic cervical cancer portends an unfavorable prognosis. The incidence and mortality rates over the last 10 years remain at a consistently high level. The backbone of treatment for metastatic cervical cancer is platinum-based combinations – the cytototic combination of paclitaxel and cisplatin (or carboplatin) being a standard-of-care treatment for patients with metastatic disease. However, chemotherapy alone failed to achieve satisfactory long-term treatment outcomes – the expected life expectancy with chemotherapeutic drugs rarely exceeds 12 months. One of the most fruitful directions in the treatment of metastatic cervical cancer to date is immunotherapy – in particular, pembrolizumab, a PD-1 pathway inhibitor – one of the key checkpoints of the immune response control. This review article highlights historical and recent achievements in metastatic cervical cancer treatment. It highlights the development of anticancer medications for advanced or metastatic cervical cancer, including targeted antiangiogenic therapy, immunotherapy, and the latest research data on the effectiveness of combining these classes of drugs with standard cytotoxic chemotherapy to achieve the best treatment outcomes.

Publisher

Remedium, Ltd.

Reference32 articles.

1. Kaprin AD, Starinskii VV, Shakhzadova AO (red.). Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2022 godu. M.: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii; 2023. 239 s. Rezhim dostupa: https://oncology-association.ru/wp-content/uploads/2023/08/sop-2022-el.versiya_compressed.pdf.

2. Kaprin AD, Starinskii VV, Shakhzadova AO (red.). Zlokachestvennye novoobrazovaniya v Rossii v 2021 godu (zabolevaemost' i smertnost'). M.: MNIOI im. P.A. Gertsena − filial FGBU «NMITs radiologii» Minzdrava Rossii; 2022. 252 s. Rezhim dostupa: https://oncology-association.ru/wp-content/uploads/2022/11/zlokachestvennye-novoobrazovaniya-vrossii-v-2021-g_zabolevaemost-i-smertnost.pdf.

3. Gardner AB, Charo LM, Mann AK, Kapp DS, Eskander RN, Chan JK. Ovarian, uterine, and cervical cancer patients with distant metastases at diagnosis: most common locations and outcomes. Clin Exp Metastasis. 2020;37(1):107–113. https://doi.org/10.1007/s10585-019-10007-0.

4. Moore DH, Blessing JA, McQuellon RP, Thaler HT, Cella D, Benda J et al. Phase III Study of Cisplatin With or Without Paclitaxel in Stage IVB, Recurrent, or Persistent Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. J Clin Oncol. 2004;22(15):3113–3119. https://doi.org/10.1200/JCO.2004.04.17.

5. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH et al. Phase III Trial of Four Cisplatin-Containing Doublet Combinations in Stage IVB, Recurrent, or Persistent Cervical Carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol. 2009;27(28):4649–4655. https://doi.org/10.1200/JCO.2009.21.8909.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3